CLINICAL_TRIALS
withdrawal
· 2026-03-12
Clinical Trial Update: Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome [Phase 2]
Summary
A Phase 2 clinical trial evaluating efgartigimod for Guillain-Barré syndrome has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chafic Karam | Conditions: Guillain-Barre Syndrome | Phase 2 | Status: WITHDRAWN